Skip to main content

Together we are beating cancer

Donate now

NHS treatment decision

Showing 12 out of 25 results
Cancer Research UK scientists in the lab

NHS England will offer the newly-approved dabrafenib plus trametinib combination to children and young people whose gliomas are being driven by a specific genetic mutation. NHS England will offer the newly-approved dabrafenib plus trametinib combination to children and young people whose gliomas are being driven by a specific genetic mutation.

by Tim Gunn | News | 13 June 2024

13 June 2024

Endometrial adenocarcinoma cells viewed under the microscope

Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer Dostarlimab (also called Jemperli) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat some types of advanced or recurrent womb cancer

by Jacob Smith | News | 8 March 2024

8 March 2024

3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer. 3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.

by Harry Jenkins | News | 19 January 2022

19 January 2022

Non small cell lung cancer cells stained in pleural effusion sample.

A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE). A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).

by Harry Jenkins | News | 12 January 2022

12 January 2022

Melanoma cell. Credit: Dr Erik Sahai

The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer. The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.

by Harry Jenkins | News | 21 December 2021

21 December 2021

Lung cancer cell

More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence. More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.

by Harry Jenkins | News | 1 December 2021

1 December 2021

Lung cancer cells

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected. Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

by Harry Jenkins | News | 11 November 2021

11 November 2021

3D representation of oesophageal cancer

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer. The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

by Harry Jenkins | News | 20 October 2021

20 October 2021